---
document_datetime: 2023-09-21 21:52:41
document_pages: 31
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/emtriva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: emtriva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 19.7676054
conversion_datetime: 2025-12-25 00:27:58.218787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Emtriva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0141              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 18/04/2023                          |                                             | SmPC and PL                      |           |
| WS/2331              | This was an application for a variation following a worksharing procedure according to Article 20 of                                      | 10/11/2022                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | Regulation (EC) No 1234/2008. - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                             |            |            |    | Commission C.I.z Veterinary   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-------------------------------|
| IG/1456 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                            | 08/11/2021 | n/a        |    |                               |
| IG/1412 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                            | 28/07/2021 | n/a        |    |                               |
| N/0137  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                        | 17/05/2021 | 17/06/2021 | PL |                               |
|         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name | 06/11/2020 | n/a        |    | IB/0135/G                     |

<div style=\"page-break-after: always\"></div>

|                    | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                 |            |            |                            |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-----------------------------------|
| PSUSA/1209/ 202004 | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/10/2020 | n/a        |                            | PRAC Recommendation - maintenance |
| IA/0136/G          | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites | 27/10/2020 | n/a        |                            |                                   |
| WS/1774            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                      | 18/06/2020 | 17/06/2021 | Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                    | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                   |            |            |                        |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IG/1236            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                     | 04/05/2020 | n/a        |                        |                                   |
| PSUSA/1209/ 201904 | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                      | 31/10/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0130            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                   | 26/04/2019 | 21/10/2019 | SmPC, Labelling and PL |                                   |
| II/0127            | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                   | 29/11/2018 | n/a        |                        |                                   |
| WS/1466/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 29/11/2018 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                    | intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   |            |            |                        |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IG/1001            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                   | 23/11/2018 | n/a        |                        |                                   |
| PSUSA/1209/ 201804 | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                                                                                                                                                           | 31/10/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IG/0995            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                        | 24/10/2018 | 21/10/2019 | SmPC                   |                                   |
| N/0125             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                      | 24/07/2018 | 21/10/2019 | Labelling              |                                   |
| T/0123             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/04/2018 | 04/06/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/1209/ 201704 | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                                                                                                                                                           | 26/10/2017 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0122   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                    | 29/08/2017   | n/a        |             |                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------------------------------|
| IA/0121   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                 | 28/07/2017   | n/a        |             |                                                           |
| IG/0799   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 14/07/2017   | n/a        |             |                                                           |
| N/0118    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 12/05/2017   | 04/06/2018 | PL          |                                                           |
| IA/0117   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                           | 03/03/2017   | n/a        |             |                                                           |
| IG/0745   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 28/11/2016   | n/a        |             |                                                           |
| II/0113   | Update of sections 4.2, 4.4 and 4.8 of the SmPC in                                                                                                                                                                                         | 15/09/2016   | 03/11/2016 | SmPC and PL | Renal insufficiency: Emtricitabine is eliminated by renal |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Emtriva 200 mg hard capsule every 24 to 48 hours in patients with renal impairment (eGFRCG â‰¥ 30 mL/min) and corresponding update the SmPC for Emtriva 10mg/ml oral solution. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | order to allow administration of   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             | Patients with renal impairment: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency. Dose or dose interval adjustment is required in all patients with creatinine clearance < 30 ml/min).   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1209/ 201604 | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                                                                                                                                                         | 27/10/2016 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                     |
| IG/0725            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                        | 21/10/2016 | n/a        |             |                                                                                                                                                                                                                                                                                       |
| WS/0860/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 26/05/2016 | n/a        |             |                                                                                                                                                                                                                                                                                       |
| WS/0792            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                       | 01/04/2016 | 24/06/2016 | SmPC and PL | Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants                                                      |

<div style=\"page-break-after: always\"></div>

|         | Update of section 4.4 of the SmPC in order to revise the HIV class label wording on mitochondrial dysfunction following the review of existing data on mitochondrial toxicity including the Mitochondrial Toxicity in Children (MITOC) Study. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, that present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0884 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                  | 28/01/2016 | 24/06/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0109 | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                | 24/11/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0613 | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                    | 14/10/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| PSUSA/1209/ 201504   | Periodic Safety Update EU Single assessment - emtricitabine                                                                                                                                                                                                                                                                                    | 08/10/2015   | n/a        |                        | PRAC Recommendation - maintenance   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IG/0614              | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                     | 02/10/2015   | n/a        |                        |                                     |
| IG/0595              | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                | 04/08/2015   | n/a        |                        |                                     |
| IG/0583              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                  | 23/07/2015   | n/a        |                        |                                     |
| IB/0103              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                 | 26/06/2015   | 24/06/2016 | SmPC, Labelling and PL |                                     |
| IG/0521              | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                     | 26/02/2015   | 30/03/2015 | Annex II and PL        |                                     |
| IB/0101/G            | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 04/12/2014   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

| PSUV/0096   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                       | 09/10/2014   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0479     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                          | 17/09/2014   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IG/0469     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                              | 07/08/2014   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IG/0448     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                 | 02/07/2014   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IG/0422     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                              | 28/03/2014   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/0530     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 'Special warnings and precautions for use' of the SmPC for Atripla, Emtriva, Eviplera, Stribild, Truvada, Viread and Vitekta to revise the wording regarding the risk of | 20/03/2014   | 30/03/2015 | SmPC, Labelling and PL | During recent years conclusive evidence has been collected which shows that the risk for HIV patients, who are well treated, to sexually transmit HIV to their partner is exceedingly low. A position statement on the use of antiretroviral therapy to reduce HIV transmission was published by the British HIV Association (BHIVA) in January 2013. As a consequence, the recommendations for post- exposure prophylaxis have also been changed in recently |

<div style=\"page-break-after: always\"></div>

|           | sexual transmission of HIV infection following CHMP request adopted in December 2013. The PL has been updated accordingly. Furthermore, the MAH took the opportunity of this worksharing to update the PL with the details of the local representatives for Croatia and to introduce the Croatian language annexes for Emtriva and to update the bottle label to include the EDQM short standard term for the pharmaceutical form for Stribild. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |     | updated HIV treatment guidelines. For example, the 2013 BHIVA guideline does not generally recommend post- exposure prophylaxis (PEP) after exposure from a patient with well treated HIV. Based on these data, the wording on the risk of transmission for HIV products was revised to reflect the current scientific knowledge. While effective suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0378   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                     | 29/11/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0092/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                             | 27/11/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IG/0368   | B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/11/2013 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0422 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. This is a type IB variation application following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008, to introduce an alternative manufacturer and release testing site of the active substance emtricitabine. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                               | 24/10/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/0391 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information regarding autoimmune disorders in relation to Immune Reactivation Syndrome, following a class labelling for antiretrovirals as requested by the CHMP. The Package Leaflet was updated accordingly. In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, Annex II is being brought in line with | 30/05/2013 | 01/07/2013 | SmPC, Annex II and PL | Upon review of safety data and literature on immune disorders in association with antiretrovirals for the treatment of HIV, the CHMP considered that there is sufficient evidence to conclude that immune reconstitution syndrome (IRS) after antiretroviral therapy may be associated with autoimmune disease/disorders even if the number of case reports is limited. Therefore, the CHMP had requested the inclusion of information on immune disorders under immune reconstitution as a class labelling for all antiretrovirals for the treatment of HIV. |

<div style=\"page-break-after: always\"></div>

|         | changes are implemented in the SmPC. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0089 | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                               | 03/05/2013 | n/a |
| IG/0294 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                     | 03/04/2013 | n/a |
| IG/0290 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                    | 03/04/2013 | n/a |
| IA/0085 | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                               | 28/08/2012 | n/a |
| IG/0203 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                  | 03/08/2012 | n/a |
| IG/0166 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                                                                                                                         | 13/04/2012 | n/a |

<div style=\"page-break-after: always\"></div>

|           | the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0082   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/01/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IG/0114/G | This was an application for a group of variations. C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                          | 17/10/2011 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0115   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics, Annex II, Labelling and Package Leaflet following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the Product information (PI) in line with the SmPC Guideline, revision 2, September 2009 and the current QRD template version 7.3.1. The MAH took this opportunity to harmonize the PI across the products Viread, Emtriva, Truvada and Atripla. Following CHMP request, section 4.6 \"fertility, pregnancy and lactation\" of the SmPC was updated | 23/06/2011 | 27/07/2011 | SmPC, Annex II, Labelling and PL | The MAH took this opportunity to harmonize the PI across the products Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate). Following CHMP request section 4.6 of the SmPC on fertility, pregnancy and lactation was revised. A moderate amount of data mainly from the Antiretroviral Pregnancy Registry on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformations or foetal / neonatal toxicity associated with tenofovir disoproxil fumarate nor with emtricitabine. |

<div style=\"page-break-after: always\"></div>

|         | Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: From Data to Labelling (EMEA/CHMP/203927/2005). In addition a number of minor linguistic amendments were implemented. Furthermore the contact details of the local representatives in the PL were updated. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                   |            |     |                 | according to the   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|--------------------|
| IG/0078 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                              | 14/07/2011 | n/a |                 |                    |
| IA/0077 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/04/2011 | n/a | Annex II and PL |                    |
|         | This was an application for a group of variations. C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance | 10/03/2011 | n/a | Annex II        | IG/0047/G          |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0048 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                       | 21/10/2010 | 21/10/2010 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0074 | Update of section 4.4 of the SmPC to include a recommendation not to discontinue Emtriva in patients co-infected with HIV and HBV with advanced liver disease or cirrhosis. Update of section 4.8 to add angioedema. Furthermore, following CHMP request this section was fully revised to be in line with the SmPC guideline. Sections 3 and 4 of the PL were updated accordingly. Update of Summary of Product Characteristics and Package Leaflet | 22/07/2010 | 26/08/2010 | SmPC and PL | Emtricitabine shows clinical and in vitro activity against HBV. Post-treatment hepatic flares were reported following discontinuation of emtricitabine. Therefore, section 4.4 of the SmPC was updated to not to discontinue Emtriva in patients co-infected with HIV and HBV with advanced liver disease or cirrhosis since post treatment exacerbations of hepatitis may lead to hepatic decompensation. The term 'angioedema', was included in section 4.8 following a review of angioedema. This review was submitted by the MAH for Truvada (emtricitabine/tenofovir DF) and identified two cases of angioedema with Truvada, with indirect evidence of a causal association with emtricitabine (a negative rechallenge to the tenofovir component of Truvada). In addition, there were four cases of a positive rechallenge to Truvada which should also be considered as possibly causally related, as the positive result could have been in response to either the tenofovir DF or the emtricitabine component. This adverse reaction, which was identified through post- |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                             |            |     |                 | marketing surveillance, was not observed in randomised controlled clinical trials in adults or paediatric HIV clinical trials of emtricitabine. The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies. Furthermore, following CHMP request the MAH has compiled a summary of the safety data supporting each ADR term in Section 4.8 of the Emtriva SmPC, which were previously submitted and approved by the CHMP. All ADRs (except angioedema) currently in section 4.8, were identified in the pivotal clinical HIV studies for Emtriva (in adults), and were included in the SmPC at the time of authorisation. Section 4.8 was fully revised to be in line with the SmPC guideline.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0076 | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH | 13/08/2010 | n/a | Annex II        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0075 | IA_09_Deletion of manufacturing site                                                                                                                                                                        | 20/11/2009 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0073 | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                                                | 29/05/2009 | n/a | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0072 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                    | 29/05/2009 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0070   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                                                                                                                                            | 12/05/2009   | n/a        |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| IB/0069   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                          | 20/04/2009   | n/a        |                 |
| II/0062   | The Marketing Authorisation Holder applied for the addition of two manufacturing sites as a manufacturing and testing sites for emtricitabine active substance. Consequential addition of alternative specifications for reagents were also proposed. Change(s) to the manufacturing process for the active substance | 22/01/2009   | 26/01/2009 |                 |
| IA/0065   | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                                                                                                                                                          | 10/11/2008   | n/a        | Annex II and PL |
| IA/0066   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                      | 05/11/2008   | n/a        |                 |
| IA/0068   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                   | 04/11/2008   | n/a        |                 |
| IA/0067   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                     | 04/11/2008   | n/a        |                 |
| IA/0064   | IA_22_a_Submission of TSE Ph. Eur. certificate for                                                                                                                                                                                                                                                                    | 04/11/2008   | n/a        |                 |

<div style=\"page-break-after: always\"></div>

|         | exc. - Approved/new manufacturer                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0063 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                  | 04/11/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0061 | IA_09_Deletion of manufacturing site                                                                 | 04/11/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0060 | IA_09_Deletion of manufacturing site                                                                 | 04/11/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0059 | IA_09_Deletion of manufacturing site                                                                 | 04/11/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0055  | Renewal of the marketing authorisation.                                                              | 24/07/2008 | 22/09/2008 | SmPC, Annex II, Labelling and PL | Based on the review of the avilable information and on the basis of a re-evaluation of the benefit-risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficientely demonstrated and therefore considered that the benefit risk of Emtriva continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. |
| IB/0057 | IB_33_Minor change in the manufacture of the finished product                                        | 29/07/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0056 | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release | 29/07/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0058 | IA_09_Deletion of manufacturing site                                                                 | 07/07/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0054 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                  | 31/03/2008 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IA/0053   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                            | 20/02/2008   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                           | 19/10/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0051   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                           | 19/10/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0050   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                           | 19/10/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0048   | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                         | 14/09/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0044   | Update of Summary of Product Characteristics and Package Leaflet Update of section 4.8 of the SPC and section 4 of the PL to list anaemia as an adverse drug reaction to emtricitabine treatment in adult patients, as requested by the CHMP in March 2007. Update of Summary of Product Characteristics and Package Leaflet | 19/07/2007   | 22/08/2007 | SmPC and PL | In a cumulative review of anaemia cases in adult patients on treatment with emtricitabine, 28 cases were identified up to 19 June 2006. Based on these cases a causal relationship between emtricitabine and anaemia was reasonably suspected. However, detailed description of the analysis performed in adult study data was needed to draw a definitive conclusion. The additional data provided from 3 trials suggested that emtricitabine can cause Grade 1 and Grade 2 anaemia, which occurs in between 0.5 and 1.0% of patients. Based on the available data, it was agreed to add \"anaemia\" to the list of uncommon adverse reactions to emtricitabine treatment in adult patient. Anaemia was already listed as common adverse reaction with emtricitabine treatment in paediatric patients. |
| IB/0049   | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                                                                                                                                         | 19/07/2007   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0047   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                             | 19/07/2007   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0045   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                                                                                                                                                                                                                      | 19/07/2007   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0046   | IA_32_b_Change in batch size of the finished product - downscaling down to 10-fold                                                                                                                                                                                                                                        | 03/07/2007   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0043   | Quality changes - change to the synthesis process of the active substance. Change(s) to the manufacturing process for the active substance                                                                                                                                                                                | 21/06/2007   | 27/06/2007 |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0040   | Update of sections 4.2 and 5.2 of the SPC to reflect results of a study evaluating the pharmacokinetics and safety of emtricitabine in neonates and young infants over the first 3 months of life, at CHMP request further to the assessment of this study in November 2006. Update of Summary of Product Characteristics | 22/03/2007   | 25/04/2007 | SmPC | An open label pharmacokinetic study of emtricitabine over the first 3 months of life following multiple dose administration in children born to HIV 1 infected mothers was completed by 20 of the 22 neonates enrolled. All the 20 neonates received two 4-day courses of emtricitabine oral solution between the first week of life and 3 months of age at a dose level of 3 mg/kg once daily (half of the approved dose for infants aged more than 4 months). Results showed that steady state clearance increased with age over the first 3 months of life and AUC decreased in parallel. Moreover, plasma emtricitabine exposure (AUC) in infants up to 3 months of age who received 3 mg/kg emtricitabine once daily was similar to that observed using 6 mg/kg daily doses in HIV-infected adults and children aged 4 months and over. This information is now included |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  | in the SPC. Furthermore, it is also mentioned that there is no efficacy data and only very few data in terms of safety are available for infants aged below 4 months. Therefore, Emtriva is not recommended for use in those aged less than four months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0042 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/04/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0039 | Update of sections 4.2 and 4.4 of the SPC in regard of the potential Hepatitis B Virus reactivation after treatment discontinuation with emtricitabine. Section 4.4 is updated to not recommend the concomitant use with other products containg emtricitabine or lamivudine. Section 4.8, in line with the MedDRA - system organ class, was updated with regards nervous system disorders and psychiatric disorders.The PL has been updated accordingly. The MAH has amended the SPC, Annex II, labelling and the PL in line with the latest QRD templates and have introduced minor linguistic changes to the some EU languages, as relevant. Update of Summary of Product Characteristics, | 22/02/2007 | 27/03/2007 | SmPC, Annex II, Labelling and PL | The results of an evaluation of post-treatment exacerbations of hepatitis performed by the MAH across 3 randomised, double-blind clinical trials of emtricitabine in patients with chronic hepatitis B were discussed in an article by Mondou et al, in Clinical Infectious Diseases, 2005; 41(5): e45-47. Based on these results the Company Core Safety Information for Emtriva was updated and now the SPC to specify that hepatitis B virus reactivation after discontinuation of treatment with emtricitabine could lead to more severe liver disease, including hepatic decompensation and liver failure. The fact that Emtriva should not be taken with any other medicinal product containing emtricitabine or lamivudine, including fixed combination products has been included in section 4.4 of the SPC and section 2 of the PL. |
| IA/0041 | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/03/2007 | n/a        | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| II/0038   | Update of sections 4.4 and 4.8 of the SPC and section 2 of the PL to implement the class labelling text on osteonecrosis, agreed by the CHMP in September 2006. Section 6 of the PL was updated with the local representatives in Bulgaria and Romania and in Belgium and Luxembourg. Update of Summary of Product Characteristics and Package Leaflet   | 14/12/2006   | 12/01/2007   | SmPC and PL   | Cases of osteonecrosis (death of the bone tissue resulting from an insufficient blood supply) have been reported in HIV-infected patients since the end of the 80's. Although the cause of this disease could be due to multi factors (including the use of corticosteroids, alcohol consumption, severe immunosuppression, higher body mass index) it has occurred specially in patients with HIV advanced disease and/or in patients with long term use of combination antiretroviral therapy (CART). Further to the review of all available data the CHMP agreed that this information should now be included in the SPC and PL of all antiretroviral medicinal products. Patients should be warned to seek medical advice in case they experience joint stiffness, aches and pain especially of the hip, knee and shoulder or if they experienced any difficulty in movement.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0034   | IB_31_b_Change to in-process tests/limits during manufacture - addition of new tests/limits                                                                                                                                                                                                                                                              | 27/09/2006   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0032   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                                                                                                                                                                                                                                                     | 23/08/2006   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0031   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                            | 23/08/2006   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0036   | IA_23_b_Change in source of excip./reagent to veg./synthetic material - other cases                                                                                                                                                                                                                                                                      | 10/08/2006   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0035   | IA_32_b_Change in batch size of the finished product - downscaling down to 10-fold                                                                                                                                                                                                                                                                       | 10/08/2006   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IA/0033   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                       | 08/08/2006   | n/a        |             |                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------|
| IA/0037   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 04/08/2006   | n/a        |             |                                                       |
| N/0030    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                 | 31/07/2006   | n/a        | PL          |                                                       |
| IA/0029   | IA_43_a_01_ Add./replacement/del. of measuring or administration device - addition or replacement                                                                | 17/05/2006   | n/a        |             |                                                       |
| II/0026   | Quality changes Quality changes                                                                                                                                  | 23/03/2006   | 27/04/2006 | SmPC        |                                                       |
| IA/0028   | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                       | 24/03/2006   | n/a        |             |                                                       |
| IA/0027   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                | 24/03/2006   | n/a        |             |                                                       |
| N/0025    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                 | 23/01/2006   | n/a        | PL          |                                                       |
| IB/0024   | IB_10_Minor change in the manufacturing process of the active substance                                                                                          | 05/12/2005   | n/a        |             |                                                       |
| II/0023   | Update sections 4.8, 5.1 and 5.2 of the SPC and                                                                                                                  | 13/10/2005   | 15/11/2005 | SmPC and PL | Further to the 24-week data results of two paediatric |

<div style=\"page-break-after: always\"></div>

|         | section 4 of the PL to reflect the results of 48 week data from three clinical studies in HIV infected paediatric patients. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                                  | studies submitted for the initial MA application the MAH provided the 48-week results of these studies and of an additional study (final report) evaluating also the pharmacokinetics, safety and antiviral effect of emtricitabine in HIV infected children. The provided data further substantiates the use of emtricitabine in HIV-1 infected children older than 4 months and the viral suppression achieved throughout the 48 weeks (89% achieved < 400 copies/ml and 77% < 50 copies/ml). A part from anaemia and skin discolouration commonly and very commonly, respectively reported in paediatric population, the pattern of adverse events reported in theses three studies is comparable with the already known for adult patients. Sections 4.8 and 5.1 of the SPC and section 4 of the PL have been updated to reflect this data.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016 | To update of section 4.4 \"Special warnings and special precautions for use\" of the Summary of Product Characteristics of Emtriva hard capsules and oral solution, to reflect the current status of the Emtriva Hepatitis B Virus development program. In addition the MAH took this opportunity to introduce minor linguistics changes to the Norwegian, Slovak, Italian, Portuguese, Spanish, Greek, Estonian, Lithuanian, Spanish, Czech, Latvian and Hungarian SPC, Package Leaflet, Labelling and Annex II, as relevant. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 27/07/2005 | 07/09/2005 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IA/0022   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                     | 10/05/2005   | n/a        |             |                                                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                     | 10/05/2005   | n/a        |             |                                                                                                                                                             |
| IA/0020   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                     | 10/05/2005   | n/a        |             |                                                                                                                                                             |
| IA/0019   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                     | 10/05/2005   | n/a        |             |                                                                                                                                                             |
| IA/0018   | IA_23_b_Change in source of excip./reagent to veg./synthetic material - other cases                                                                                                                                                                                                                                                                                                                     | 10/05/2005   | n/a        |             |                                                                                                                                                             |
| IA/0017   | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                                                                                                                                                                 | 27/04/2005   | n/a        |             |                                                                                                                                                             |
| N/0015    | To update the contact details of the Local Representatives for Estonia, Latvia, Lithuania, Iceland and Cyprus in the Package Leaflet. In addition, the MAH took this opportunity to introduce minor corrections to the existing contact details and to be in line with the latest EMEA/QRD templates.\" Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 07/04/2005   | n/a        | PL          |                                                                                                                                                             |
| II/0014   | Update of section 5.2 of the SPC, to reflect the results of a study on the effect of food on the pharmacokinetics of emtricitabine following the                                                                                                                                                                                                                                                        | 20/01/2005   | 03/03/2005 | SmPC and PL | Following the assessment of the results of a study performed to evaluate the effect of food on absorption emtricitabine from the oral solution, the CHMP in |

<div style=\"page-break-after: always\"></div>

|         | administration of Emtriva 10mg/ml oral solution, as requested by the CHMP. In addition, section 2 of the Portuguese PL was amended regarding a spelling correction. Update of Summary of Product Characteristics and Package Leaflet                                                                              |            |            |      | September 2004 concluded that having demonstrated that there is no effect on the pharmacokinetics, the MAH should amend the SPC in accordance. Therefore, section 5.2 of the SPC was updated to reflect that the oral solution can, as the hard capsules, be administered with or without food.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013 | To update section 4.4 and 4.8 of the SPC and section 2 of the PL, to implement the class labelling text regarding the Immune Reactivation Syndrome, as adopted by the CHMP. In addition the Greek PL was amended regarding spelling corrections. Update of Summary of Product Characteristics and Package Leaflet | 18/11/2004 | 17/12/2004 | SmPC | In patients treated with any type of combination antiretroviral therapy (CART), an inflammatory response to indolent or residual opportunistic infections may occur, when the immune system responds to treatment. In most cases, the inflammatory reactions towards the opportunistic pathogens in question cannot be foreseen since the opportunistic infection has not yet been detected/diagnosed. If diagnosed prior to institution of CART, the treatment against the opportunistic infection (OI) is usually given priority. In particular, this is true for the complications most feared in this context; CMV- retinitis, generalised mycobacterial infections and Pneumocystis carinii pneumonia. An additional reason for treating the OI and the HIV-infection sequentially, is the great risk of adverse events (toxicity or lack of effect) due to drug interactions. The clinical consequence of the reactivation of the immune system in patients starting CART cannot be prevented and the early recognition and diagnose of these inflammatory reaction is considering to be important to the clinical |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | handling of the patients. Therefore, the CHMP further to the assessment of MAH's responses and discussions held at the Pharmacovigilance working party and CHMP, a class labelling text regarding the reactivation of the immune system of HIV-infected patients treated with any type of combination antiretroviral therapy (CART) was agreed to be implemented in all anti-retroviral product information.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012 | Changes related to the active substance emtricitabine (i.e. changes related to the synthesis, control, specification and packaging). Quality changes                                                                                                                                                                                                                          | 21/10/2004 | 27/10/2004 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                |
| N/0011  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                              | 16/08/2004 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0006 | Update of section 5.3 of the SPC with new preclinical safety information following the completion of two years carcinogenicity studies. In addition the PL and Labelling were updated to be in line with the latest EMEA/QRD templates. Minor linguistic changes were introduced in the Dutch PL. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 23/06/2004 | 02/08/2004 | SmPC, Labelling and PL | When the initial MA was granted, long term carcinogenicity studies were ongoing. The submission of these long-term studies reports fulfil the commitment made by the MAH within the initial MA and are the basis for the application of this type II variation. The preclinical safety data section of the SPC was update to reflect the negative carcinogenic potential results of these studies.             |
| IB/0010 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                    | 19/07/2004 | n/a        | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0009 | IB_42_a_02_Change in shelf-life of finished product - after first opening                                                                                                                                                                                                                                                                                                     | 19/07/2004 | n/a        | SmPC, Labelling and    |                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005 | Update of section 4.4 of the SPC and section 2 of the PL, to implement the class labelling text regarding the mitochondrial toxicity in children with in utero and post-natal exposure to Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs), as adopted by the CPMP. In addition, section 6.4 of the SPC and sections 5 and 6 of the PL were updated in line with the latest EMEA/QRD templates. Update of Summary of Product Characteristics and Package Leaflet | 26/03/2004 | 23/06/2004 | SmPC and PL | The issue of mitochondrial toxicity in children of in utero and/ or post-natal exposure to NRTIs was first raised in 1999 following the identification of 8 cases of mitochondrial dysfunction in uninfected children included in a clinical trial. The MAHs for all NRTIs were asked to provide preclinical data on the mitochondrial toxicity and a review of adverse events potentially attributable to mitochondrial toxicity in children exposed in utero and / or post-natally to NRTIs. Following the assessment of the submitted data and discussions held at the PhVWP and CPMP, a class labelling wording was agreed by the CPMP in November 2003 to be implemented in all NRTIs product information. In addition, the storage conditions in section 6.4 of the SPC and section 5 of the PL were updated in line with EMEA/QRD templates. The list of the local representatives for the current European Members States and for the 10 new accession Members was introduced in section 6 of the PL. |
| IB/0008 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                                                                                                                                   | 08/06/2004 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0001 | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2004 | 26/01/2004 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0004 | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                                                               | 17/11/2003 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0003 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                               | 17/11/2003 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0002   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold   | 17/11/2003   | n/a   |
|-----------|------------------------------------------------------------------------------------|--------------|-------|